Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination of both medicines, however, did not achieve a statistically significant reduction in LVH over losartan alone.
You may also be interested in...
Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Fixed-dose blood pressure pill will reach market in early February, Novartis tells “The Pink Sheet” DAILY.
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.